FDA Announces It Will Evaluate the Potential Heart Risks of Benicar

The U.S. Food and Drug Administration (FDA) has announced it will investigate the possible increased health risk of hypertension drug Benicar. This comes after disturbing data revealed by two clinical trials indicating that Benicar may lead to an increased risk of heart attack, stroke and sudden death. Benicar falls under a category of drugs called angiotensin-receptor blockers (ARBs).

During the clinical trials, originally conducted to determine whether Benicar could slow the progression of kidney disease, surprising results showed an increased risk of heart failure, stroke and sudden death among type 2 diabetes patients who were taking Benicar versus those taking a placebo.

As it conducts its investigation, the FDA is asking both patients and medical professionals to immediately report any adverse side effects of Benicar.

If you or a loved one has been harmed while on Benicar, you may be eligible to receive compensation. To learn more, please contact AWKO, Pensacola’s most experienced defective drug legal team, at (888) 255-2956.